Taiho Pharmaceutical Company

Taiho Pharmaceutical Co., Ltd. is a pharmaceutical company based in Tokyo, Japan, established in June 1963. The company specializes in the research, development, production, distribution, and marketing of pharmaceutical products, with a strong focus on oncology. Taiho develops a range of cancer treatments, including S-1 for gastric cancer and TAS-102 for colorectal cancer. In addition to oncology drugs, the company also produces controlled medical devices and various classes of over-the-counter medications. Through its commitment to developing innovative therapies, Taiho aims to improve the lives of patients and support healthcare professionals in oncology and other medical fields.

Teruhiro Utsugi

Senior Managing Director

5 past transactions

Araris Biotech

Acquisition in 2025
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

StapleBio

Venture Round in 2024
StapleBio is a biotechnology company dedicated to researching and developing pharmaceuticals using staple nucleic acid technology. Its core platform enables precise regulation of gene expression through the formation of G-quadruplex structures, targeting various diseases including cancer, CNS disorders, autoimmune diseases, viral infections, and rare genetic conditions.

Cullinan Pearl

Acquisition in 2022
Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

AuB

Series A in 2019
Founded in Japan in 2015, AuB specializes in developing supplements, foods, and beverages designed to enhance the intestinal environment of athletes. The company's products are based on research into microbiome and stool samples from athletes, aiming to improve performance and overall human health.

Quentis Therapeutics

Series A in 2018
Quentis Therapeutics, Inc. is a biotechnology company founded in 2016 and based in New York, specializing in the development of cancer immunotherapies. The company's innovative therapeutics focus on modulating endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By targeting these pathways, Quentis Therapeutics aims to enhance the immune system's ability to combat cancer, thereby providing patients with access to novel treatment options. The company's approach seeks to translate cutting-edge biological insights into effective therapeutic strategies that can improve anti-tumor immunity.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.